32 Biosciences revealed its plan to launch a $40 million Series A at this year’s J.P Morgan Healthcare conference, to advance ...
Johnson & Johnson continues its $55 billion investment in U.S. operations (first announced back in 2025), targeting ...
Eli Lilly and Company and Ventyx Biosciences entered into a definitive agreement under which Eli Lilly will acquire Ventyx in ...
In the third part of her conversation with PharmExec, Trialynx founder and CEO Angela Schwab discusses the causes and ...
In today’s Pharmaceutical Executive Daily, the FDA moves to limit regulation of non-medical fitness wearables, industry ...
The "Pharmaceutical Current Good Manufacturing Practices (CGMPs) for the 21st Century--A Risk Based Approach" initiative was ...
PE: How is AI supporting clinical trial design? Schwab: We have a hit a new era of clinical trial design. Up until 2024, ...
Nimbus Therapeutics announced it has entered into a multi-year research collaboration and $1.3 exclusive license agreement ...
The collaboration with Sanofi focuses on developing bispecific antibodies for autoimmune diseases, leveraging predictive ...
Amgen’s acquisition of Dark Blue Therapeutics adds a first-in-class leukemia program that aligns with the company’s growing ...
GSK announced it has entered a multi-year strategic collaboration agreement with Helix aiming to drive the development of ...
In today’s Pharmaceutical Executive Daily, Amgen announces an $840 million acquisition of Dark Blue Therapeutics, GSK enters ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback